Technology
Notice to the Annual General Meeting in Hexagon AB (publ)
Published
1 year agoon
By
STOCKHOLM, April 2, 2025 /PRNewswire/ — The shareholders of Hexagon AB are invited to attend the Annual General Meeting (AGM) to be held at 17:00 CET on Monday 5 May 2025, at IVA Conference Center, Grev Turegatan 16, Stockholm.
The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen) and the company’s Articles of Association, decided that shareholders shall be able to exercise their voting rights by postal voting before the General Meeting. Consequently, shareholders may choose to exercise their voting rights at the AGM by attending in person, through a proxy or by postal voting.
A. PARTICIPATION IN PERSON OR BY PROXY
Shareholders who wish to attend the AGM must:
firstly, be recorded as shareholders in the share register maintained by Euroclear Sweden AB on Thursday 24 April 2025, and
secondly, notify the company of their attendance no later than Monday 28 April 2025, according to the instructions below.
Notice of attendance to the Annual General Meeting can be given on Hexagon’s website, www.hexagon.com, or by post to: Hexagon AB, “Annual General Meeting”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden,
or by phone +46 8-402 92 21, on 28 April 2025 at the latest.
When giving notice of attendance, the shareholder must state their name, personal identity number/corporate identity number, address, telephone number (daytime) and shareholding.
For shareholders who wish to be represented by a proxy, an original proxy to act on behalf of the shareholder should be attached to the notice of attendance. A proxy form will be available on the company’s website www.hexagon.com and will be sent by post to shareholders that contact the company and state their address. Representatives of a legal entity should also send a copy of the registration certificate or similar documentation of authorisation.
B. PARTICIPATION BY POSTAL VOTING
Shareholders may exercise their voting rights through postal voting. Shareholders who wish to participate in the Annual General Meeting by postal voting must:
firstly, be recorded as shareholder in the share register maintained by Euroclear Sweden AB on Thursday 24 April 2025, and
secondly, notify the company by submitting a postal vote in accordance with the instructions below, so that the postal vote is received by Euroclear Sweden AB no later than Monday 28 April 2025.
A special form must be used for the postal vote. The postal voting form is available on the company’s website www.hexagon.com. A separate notification to the Annual General Meeting is not required as the postal voting form will be considered as a notification. Completed and signed postal voting forms can be sent by mail to Hexagon AB, “Annual General Meeting”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden, or by e-mail to GeneralMeetingService@euroclear.com. Completed and signed forms must be received by Euroclear Sweden AB no later than 28 April 2025. Shareholders may also cast their votes electronically through verification with BankID via Euroclear Sweden AB’s website https://anmalan.vpc.se/EuroclearProxy, by 28 April 2025 at the latest.
Shareholders may not submit special instructions or conditions with the postal vote. In such cases, the entire postal vote will be invalid. Further instructions and conditions can be found in the postal voting form and at https://anmalan.vpc.se/EuroclearProxy.
If the shareholder submits the postal vote by proxy, a written and dated power of attorney signed by the shareholder must be attached to the postal voting form. Proxy forms are available on the company’s website www.hexagon.com and will be sent on request to shareholders who state their postal address. If the shareholder is a legal person, a registration certificate or other authorization document must be attached to the form.
Please note that shareholders who wish to attend the Annual General Meeting in person or by proxy must notify the company in accordance with the instructions under the heading “Participation in person or by proxy” above. A notification of participation by postal voting is not sufficient for shareholders who wish to attend the Annual General Meeting in person or by proxy.
C. NOMINEE-REGISTERED SHARES
To participate in the AGM, shareholders with nominee-registered shares must – in addition to notification to the company of their attendance or submission of a postal vote – request their bank or broker to have the shares owner-registered with Euroclear Sweden AB, in order for the shareholder to be recorded in the share register. Such re-registration must be made by 24 April 2025 and the nominee should be notified in due time before this date. Re-registration requested by the shareholder in such time that the registration has been completed by the nominee no later than 28 April 2025 will be taken into account in the preparation of the share register.
D. AGENDA OF THE ANNUAL GENERAL MEETING
Proposal for agenda Opening of the Meeting.Election of Chairman of the Meeting.Preparation and approval of the voting list.Approval of the agenda.Election of two persons to check the minutes.Determination of compliance with the rules of convocation.Address by the President.Presentation of
(a) the annual report and the auditors’ report, as well as the consolidated financial report and auditors’ report on the consolidated financial report for the financial year 2024,
(b) a statement from the company’s auditor confirming compliance with the guidelines for the remuneration of senior executives that have applied since the preceding Annual General Meeting, and
(c) the proposal of the Board of Directors for the dividend and statement thereon.Resolutions concerning
(a) adoption of the income statement and balance sheet, and of the consolidated income statement and consolidated balance sheet, all as per 31 December 2024,
(b) disposition of the Company’s profit as set forth in the balance sheet adopted by the Meeting and the record date for dividend distribution, and
(c) discharge of the Board of Directors and the Managing Director from personal liability.Determination of the number of members and deputy members of the Board of Directors.Determination of the fees to be paid to the board members and auditors.Election of board members and auditors.Election of members of the Nomination Committee.Resolution on approval of remuneration report.Resolution on a performance based long term incentive programme
(Share Programme 2025/2028)Authorization for the Board of Directors on acquisition and transfer of own shares.Authorization for the Board of Directors to issue shares, convertibles and/or warrants.Closing of the Meeting.
Proposals for resolutions
Election of Chairman of the Meeting (item 2)
The Nomination Committee elected in anticipation of the 2025 Annual General Meeting, comprising Mikael Ekdahl (Melker Schörling AB), Jan Dworsky (Swedbank Robur fonder), Brett Watson (Infor) and Daniel Kristiansson (Alecta) has proposed that Ola Rollén be elected Chairman of the 2025 Annual General Meeting.
Proposal for resolution on dividend (item 9 b)
For the financial year 2024, the Board of Directors proposes that a dividend of EUR 0.14 per share be declared. Wednesday 7 May 2025 is proposed as the record date for the right to receive dividend. If the Annual General Meeting so resolves, the dividend is expected to be distributed by Euroclear Sweden AB starting on Wednesday 14 May 2025. Payment is made in EUR, provided that EUR can be received by the shareholder’s yield account; if not, payment will be distributed in SEK, whereby currency exchange is made in accordance with Euroclear Sweden AB’s applicable procedures.
Proposals regarding election of board members and auditor and fees (items 10-12)
The Nomination Committee proposes the following:
The number of Board Members shall be nine, without deputies.Directors’ fees shall be paid as follows: SEK 2,700,000 to the Chairman of the Board, SEK 2,000,000 to the vice Chairman of the Board and SEK 850,000 to each of the other Board Members elected by the Annual General Meeting who are not employed by the company. As remuneration for committee work, the chairman of the Remuneration Committee shall receive SEK 115,000 and each member of the Remuneration Committee SEK 85,000 and the chairman of the Audit Committee shall receive SEK 425,000 and member of the Audit Committee SEK 315,000.Re-election of Board Members Ola Rollén, Gun Nilsson, Sofia Schörling Högberg, Märta Schörling Andreen, Erik Huggers, Annika Falkengren and Ralph Haupter and new election of Björn Rosengren and Tomas Eliasson as ordinary Board Members. John Brandon and Brett Watson have declined re-election.Re-election of Ola Rollén as the Chairman of the Board and new election of Björn Rosengren as vice Chairman of the Board.Re-election of auditing firm PricewaterhouseCoopers AB as the company’s auditor for a period of one year, i.e., until the end of the Annual General Meeting 2026, in accordance with the recommendation from the Audit Committee, whereby it is noted that the auditing firm has notified that the authorised public accountant
Bo Karlsson will be appointed principally responsible auditor.Fees to auditor shall be payable according to contract.
Björn Rosengren (born 1959) has a long and diverse career in the business sector, most recently serving as CEO and Group President of ABB Ltd. Prior to this, Björn was the CEO of Sandvik, CEO of Wärtsilä and Deputy CEO of Atlas Copco. Björn is also an honorary doctor at the University of Vaasa and a board member of the World Childhood Foundation. Björn holds a Master of Science in Mechanical Engineering from Chalmers University of Technology. Björn is considered independent in relation to the company and its management as well as major shareholders of the company. Björn (including related natural and legal persons) owns 332,873 shares in the company.
Tomas Eliasson (born 1962) has extensive experience as a board member in several publicly listed companies. Currently, Tomas is a board member in Telia, Millicom International Cellular S.A, Boliden and Elekta, but Tomas has announced that he is leaving the Board of Directors of Millicom International Cellular S.A. in connection with the Annual General Meeting 2025. Tomas has previously served as CFO of Sandvik, Electrolux, Assa Abloy and Seco Tools. Tomas holds a Master of Science in Business and Economics from Uppsala University. Tomas is considered independent in relation to the company and its management as well as major shareholders of the company. Tomas (including related natural and legal persons) owns no shares in the company.
Proposal for election of members of the Nomination Committee (item 13)
Shareholders representing in total approximately 53 per cent of the number of votes in the company recommend that the AGM resolves as follows regarding the Nomination Committee in respect of the AGM 2026:
The Nomination Committee shall have four members.Re-election of Mikael Ekdahl (Melker Schörling AB), Jan Dworsky (Swedbank Robur fonder), Brett Watson (Infor) and Daniel Kristiansson (Alecta) as members of the Nomination Committee in respect of the Annual General Meeting 2026. The Chairman of the Board shall be co-opted to the Nomination Committee.Re-election of Mikael Ekdahl as Chairman of the Nomination Committee.In case a shareholder, whom a member of the Nomination Committee represents, is no longer one of the major shareholders of Hexagon, or if a member of the Nomination Committee is no longer employed by such shareholder, or for any other reason leaves the Committee before the Annual General Meeting 2026, the Committee shall be entitled to appoint another representative among the major shareholders to replace such member.
Resolution on approval of remuneration report (item 14)
The Board of Directors proposes that the Annual General Meeting resolves to approve the Board of Director’s report regarding compensation pursuant to Chapter 8,
Section 53 a of the Swedish Companies Act.
Proposal for resolution on a performance based long term incentive programme (Share Programme 2025/2028) (item 15)
The Board of Directors proposes that the General Meeting resolves on implementation of a performance based long-term share programme for 2025 (“Share Programme 2025/2028”) for the group management, division managers, senior executives and key employees within the Hexagon Group as follows.
The rationale for the proposal
The purpose of Share Programme 2025/2028 is to strengthen the Hexagon Group’s ability to retain and recruit competent employees, provide competitive remuneration and to align the interests of the shareholders with the interests of the employees concerned. Through a share-based incentive programme, the employees’ remuneration is tied to the company’s earnings and value growth and creates long-term incentives for the programme participants. In light of the above, the Board of Directors believes that the implementation of Share Programme 2025/2028 may have a positive effect on the long-term value growth of the Group and, consequently, that Share Programme 2025/2028 is beneficial to both the shareholders and the company.
Participants in Share Programme 2025/2028 and allocation
Share Programme 2025/2028 is proposed to include a maximum of approximately
2,000 senior executives and key employees within the Hexagon Group, who are divided into five groups: the President and CEO (“Group 1”), group management (“Group 2”), division managers (“Group 3”) and other senior executives and key employees (“Group 4” and “Group 5”). Invitation to participate in the programme shall be provided by Hexagon on or about 30 June 2025. Participation in Share Programme 2025/2028 requires that the participant, except for the President and CEO, has been employed by the Hexagon Group for at least twelve (12) months prior to the date of the offer.
Participants are offered to be allocated performance awards that may entitle to Series B shares according to the conditions set out below. The performance awards shall be based on a maximum value for each participant category. The maximum value for the participants in Group 1 will be 100 per cent of the participant’s annual base salary for 2025, for participants in Group 2, 50 per cent of the participant’s annual base salary for 2025, for participants in Group 3 and Group 4, 100 per cent of the participant’s annual base salary for 2025, and for participants in Group 5, 35 per cent of the participant’s annual base salary for 2025. The total sum of the maximum values of the performance awards thus defined for all participants will not exceed EUR 60 million, including social costs.
The share price used to calculate the number of shares to which the performance awards yields will be the volume-weighted average of the market price of Hexagon Series B shares on Nasdaq Stockholm during a period of five (5) trading days before the day the participants are offered to participate in the programme.
Performance condition
Allocated performance awards entitle to the receipt of Series B shares in the company provided that the performance condition related to the development of Hexagon’s earnings per share[1] during the measurement period 1 January 2025 until 31 December 2028 is fulfilled, where the last financial year during the measurement period is compared with the financial year preceding the measurement period, with reservation for any reduction in the number of shares in accordance with the terms of Share Programme 2025/2028. The target level for the performance-based condition shall be an increase in the company’s earnings per share during the financial year 2028 compared to the financial year 2024. If the target level is achieved, the participants shall be entitled to receive Series B shares in the company in accordance with the terms of Share Programme 2025/2028. The Board of Directors intends to present the fulfillment of the performance-based condition in the annual report for the financial year 2028.
Other conditions
In addition to the above conditions, the following shall apply for the performance awards.
Performance awards shall be granted free of charge after the Annual General Meeting.Each performance award entitles the holder to receive one Series B share in the company free of charge approximately four (4) years after allotment of the award (vesting period), provided that the above performance condition has been met and that the holder has been employed by the Hexagon Group during the entire measurement period and is still employed at the time of the release of the interim report for the first quarter 2029. Exemptions to the requirement of employment during the entire measurement period up to and including the time of the release of the interim report for the first quarter 2029 may be granted by the Board of Directors in specific cases, including, but not limited to, a participant’s disability or retirement.The Board of Directors shall have the opportunity to make adjustments as a result of extraordinary events such as bonus issue, share split, rights issue, and/or other similar events.The performance awards are non-transferable and may not be pledged.The performance awards can be granted by the company or any other company within the Group.
Preparation and administration
The Board of Directors shall be responsible for preparing the detailed terms and conditions and administration of Share Programme 2025/2028, in accordance with the above mentioned terms and guidelines. To this end, the Board of Directors shall be entitled to make adjustments to meet foreign regulations or market conditions. The Board of Directors may also make other adjustments, including for example a right to resolve on a reduced allotment of shares, if significant changes in the Hexagon Group, or its operational environment, would, as assessed by the Board of Directors, result in a situation where the established terms and conditions for Share Programme 2025/2028 no longer are appropriate or reasonable.
In the event that the Board of Directors considers that the delivery of shares under Share Programme 2025/2028 cannot be achieved at a reasonable cost, with reasonable administrative efforts or due to specific market conditions, the Board of Directors shall have the right to make appropriate local adjustments to the programme or instead offer participants a cash settlement.
Scope and costs of the programme
Provided that the share price for the company’s Series B share at the time of allotment of performance awards under Share Programme 2025/2028 is SEK 114.55[2], Share Programme 2025/2028 will, in accordance with the principles and assumptions set out above, comprise maximum 5,333,000 Series B shares in total, which corresponds to approximately 0.2 per cent of the total outstanding shares in the company.
Provided that the performance condition is fully met, the total costs for Share Programme 2025/2028, in accordance with the principles and assumptions set out above, is estimated to a maximum of approximately EUR 60 million, allocated over the vesting period. Estimated social costs and administration costs for the programme are included in the amount.
In the event that the total costs of Share Programme 2025/2028 would exceed EUR 60 million, the total number of allocated Series B shares in Hexagon will be reduced so that the total costs of Share Programme 2025/2028 will not exceed this amount. Such reduction will be made pro rata in relation to the highest value for each participant category in accordance with the above.
Delivery of shares under Share Programme 2025/2028
To ensure the delivery of Series B shares under Share Programme 2025/2028, the company intends to enter into an agreement with a third party on terms in accordance with market practice, under which the third party shall, in its own name, acquire and transfer Series B shares in the company to the participants in accordance with Share Programme 2025/2028.
Preparation of the proposal
Share Programme 2025/2028 has been initiated by the Board of Directors of Hexagon and has been structured in consultation with external advisers. Share Programme 2025/2028 has been prepared by the Remuneration Committee and reviewed at meetings with the Board of Directors.
Previous incentive programmes in Hexagon
For a description of Hexagon’s other incentive programmes, Share Programme 2022/2025, Share Programme 2023/2026 and Share Programme 2024/2027, please see the company’s Annual Report 2024, note 30, and the company’s website www.hexagon.com. In addition to the programmes described therein, there are no other long term incentive programmes in Hexagon.
Resolution on authorization for the Board of Directors on acquisition and transfer of own shares (item 16)
Hexagon has previously, on the basis of authorization by the General Meeting, acquired own Series B shares for the purpose of using repurchased shares to give the Board of Directors the opportunity to adjust the company’s capital structure, to finance potential company acquisitions, and as a hedge for the company’s share-based incentive programmes. As of 1 January 2025, the company held 21,100,000 own Series B shares, corresponding to approximately 0.8 per cent of the total number of shares in the company. The Board of Directors makes the assessment that it remains advantageous for the company to continue to be able to use repurchased shares in order to adjust the company’s capital structure, on account of potential company acquisitions and for the company’s share-based incentive programmes.
In view of the above, the Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to pass a resolution, on one or more occasions for the period up until the next Annual General Meeting, on acquisition and transfer of Series B shares in the company. Acquisition of shares may be made at a maximum of Series B shares so that the company’s holding does not exceed ten (10) per cent of all shares in the company at that time. Acquisitions of shares on Nasdaq Stockholm may only occur at a price within the share price interval registered at that time, where share price interval means the difference between the highest buying price and the lowest selling price. Transfer of Series B shares may be made at a maximum of ten (10) per cent of the total number of shares in the company. A transfer may be made with deviation from the shareholders’ preferential rights on Nasdaq Stockholm as well as to third parties in connection with acquisition of a company or a business. Compensation for transferred shares can be paid in cash, through an issue in kind or a set-off. Transfers of shares on Nasdaq Stockholm may only occur at a price per share within the share price interval registered at that time, where share price interval means the difference between the highest buying price and the lowest selling price. Transfer in connection with acquisitions may be made at a market value assessed by the Board of Directors.
The purpose of the authorizations is (i) to give the Board of Directors the opportunity to adjust the company’s capital structure and thereby contribute to increased shareholder value, (ii) to enable acquisition opportunities by financing acquisitions with the company’s own shares, and (iii) to ensure the company’s undertakings, due to share-related or share-based incentive programs (other than delivery of shares to participants in incentive programs), including social security costs.
The resolution according to this item requires approval from shareholders representing at least two-thirds of both the number of votes cast as well as the shares represented at the general meeting in order to be valid.
Resolution on authorization for the Board of Directors to issue shares, convertibles and/or warrants (item 17)
The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors during the period up until the next AGM to, on one or more occasions, with or without deviation from the shareholders’ preferential rights, and with or without provisions for contribution in kind, set-off or other conditions, resolve to issue Series B shares, convertibles and/or warrants (with rights to subscribe for or convert into Series B shares). By resolutions in accordance with the authorization, the number of shares may be increased by a number corresponding to a maximum of ten (10) percent of the number of outstanding shares in the company at the time when the Board of Directors first uses the authorization.
The purpose of the authorization and the reasons for a potential deviation from the shareholders’ preferential rights as set out above, is to ensure financing of acquisitions of companies, part of companies or businesses or to strengthen the company’s capital base and equity/assets ratio. Such issues may not require amendment of the Articles of Association applicable from time to time. In case of deviation from the shareholders’ preferential rights, issues by virtue of the authorisation shall be made on market conditions. In accordance with the conditions set out above, the Board of Directors shall also be authorized to resolve on other terms as considered necessary by the Board of Directors to carry out the issues.
The Board of Directors further proposes that the Managing Director, or anyone appointed by the Managing Director, shall have the right to make any adjustments that may be necessary in connection with the registration of the resolution with the Swedish Companies Registration Office (Sw: Bolagsverket).
The resolution according to this item requires approval from shareholders representing at least two-thirds of both the number of votes cast as well as the shares represented at the general meeting in order to be valid.
E. AVAILABLE DOCUMENTS
The Annual Report and the auditor’s statement as well as the auditors’statement regarding whether the guidelines for the remuneration of senior executives have been complied with, the Board of Director’s remuneration report, the Board of Director’s complete proposal concerning items 15-17 together with related documents, as well as the Board of Director’s statement pursuant to Chapter 18, Section 4 and Chapter 19, Section 22 of the Swedish Companies Act will be kept available for the shareholders at the company’s headquarters in Stockholm no later than Monday 14 April 2025. Copies of the documents will be sent to those shareholders who request to receive such information and who have provided their address and will be available at the company’s website www.hexagon.com and at the Annual General Meeting.
F. SHAREHOLDERS’ RIGHT TO RECEIVE INFORMATION AT THE ANNUAL GENERAL MEETING
The Board of Directors and the Managing Director shall, if requested by a shareholder and the Board of Directors considers that it can be done without material damage to the company, provide information regarding issues that (i) may affect the assessment of an item on the agenda (ii) circumstances that may affect the assessment of the company’s or its subsidiaries’ financial position or information concerning (iii) the company’s relation with other companies within the group. Shareholders may send questions in advance by mail to Hexagon AB (publ), Box 3692, SE-103 59 Stockholm, Sweden or by e-mail to bolagsstamma@hexagon.com.
G. NUMBER OF SHARES AND VOTES IN THE COMPANY
The total number of shares in the company amounts to 2,705,477,888 of which 110,250,000 are shares of Series A (with 10 votes per share), and 2,595,227,888 are shares of Series B (with 1 vote per share). The total number of votes in the company amounts to 3,697,727,888. Hexagon AB (publ) holds 21,100,000 of its own Series B shares, corresponding to an equal number of votes, for which the company cannot exercise voting rights.
H. PROCESSING OF PERSONAL DATA
For information about the processing of your personal data, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. If you have questions regarding Hexagon AB’s processing of your personal data, you can contact the company by email privacy@hexagon.com. Hexagon AB (publ) has corporate ID No. 556190-4771 and the Board of Directors’ registered office is in Stockholm, Sweden.
____________________________
Stockholm in April 2025
The Board of Directors
Hexagon AB (publ)
[1] Earnings per share is defined as the company’s earnings per share, excluding adjustments.
[2] Corresponding to the closing price on 18 March 2025 for Hexagon’s Series B share on Nasdaq Stockholm.
For further information, please contact:
Tom Hull, Head of Investor Relations, +44 7442 678 437, ir@hexagon.com
Anton Heikenström, Investor Relations Manager, Hexagon AB, +46 8 601 26 26, ir@hexagon.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hexagon/r/notice-to-the-annual-general-meeting-in-hexagon-ab–publ-,c4128664
The following files are available for download:
https://mb.cision.com/Main/387/4128664/3359246.pdf
Notice to Annual General Meeting 2025
View original content:https://www.prnewswire.com/news-releases/notice-to-the-annual-general-meeting-in-hexagon-ab-publ-302418083.html
SOURCE Hexagon
You may like
Technology
Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network
Published
37 minutes agoon
July 20, 2026By
Latest independent ranking reinforces Bell’s network leadership
MONTRÉAL, July 20, 2026 /CNW/ — Bell today announced that its 5G+ network has been ranked Canada’s Fastest 5G+ Network by independent network analysts Rohde & Schwarz SwissQual AG (R&S), adding to its growing list of independent network awards.
Bell ranked first in both R&S’s Fastest 5G+ Network Data Speed Performance Score and Fastest 5G Network Data Speed Score categories based on extensive drive testing across 19 Canadian communities. The recognition builds on Bell’s recent Ookla awards for Canada’s Fastest and Best 5G Network, reinforcing Bell’s position as a leader in wireless performance through both real-world consumer testing and independent engineering analysis.
Bell’s network delivers during the moments that matter most, from everyday connections with family, friends and colleagues to Canada’s biggest cultural and sporting events. Built to perform even when demand is at its highest, Bell’s 5G+ network helped keep customers connected during major events this year, including the Formula 1 Grand Prix in Montréal, the Canadiens’ playoff run and Canada’s summer of soccer.
Since 2020, Bell has invested billions in broadband and wireless infrastructure, expanding its network with faster speeds, greater reliability and advanced capabilities for communities across Canada. This year alone, Bell has upgraded hundreds of towers from 4G to 5G with more on the way.
Quotes
“This recognition from Rohde & Schwarz is another strong validation of Bell’s strategic priority to deliver the best networks. Bell’s 5G+ network delivers the speed and performance Canadians expect, whether they’re streaming, gaming, working or staying connected on the go. Connection is everything, and we’re proud to see our continued investment recognized by another independent third party.”
– Blaik Kirby, Group President, Consumer and Small Business, Bell
“Based on our 2026 testing of national wireless networks in Canada, Bell delivered the top 5G/5G+ data performance, meaning subscribers can experience faster speeds and more reliable connections, especially in busy urban areas. At Rohde & Schwarz, independent network benchmarking is core to our mission. By providing operators with objective, real-world performance data, we help drive continuous improvement across the industry, ultimately benefiting every subscriber.”
– Axel Hansmann, CEO Rohde & Schwarz SwissQual AG
To learn more about 5G and 5G+ wireless, please visit Bell.ca/network.
About Bell
Bell is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.
1 Based on total revenue and total combined customer connections.
Media inquiries:
Patricia Garcia
media@bell.ca
Investor inquiries:
Krishna Somers
krishna.somers@bell.ca
SOURCE Bell Canada (MTL)
Technology
Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network
Published
37 minutes agoon
July 20, 2026By
Latest independent ranking reinforces Bell’s network leadership
MONTRÉAL, July 20, 2026 /CNW/ — Bell today announced that its 5G+ network has been ranked Canada’s Fastest 5G+ Network by independent network analysts Rohde & Schwarz SwissQual AG (R&S), adding to its growing list of independent network awards.
Bell ranked first in both R&S’s Fastest 5G+ Network Data Speed Performance Score and Fastest 5G Network Data Speed Score categories based on extensive drive testing across 19 Canadian communities. The recognition builds on Bell’s recent Ookla awards for Canada’s Fastest and Best 5G Network, reinforcing Bell’s position as a leader in wireless performance through both real-world consumer testing and independent engineering analysis.
Bell’s network delivers during the moments that matter most, from everyday connections with family, friends and colleagues to Canada’s biggest cultural and sporting events. Built to perform even when demand is at its highest, Bell’s 5G+ network helped keep customers connected during major events this year, including the Formula 1 Grand Prix in Montréal, the Canadiens’ playoff run and Canada’s summer of soccer.
Since 2020, Bell has invested billions in broadband and wireless infrastructure, expanding its network with faster speeds, greater reliability and advanced capabilities for communities across Canada. This year alone, Bell has upgraded hundreds of towers from 4G to 5G with more on the way.
Quotes
“This recognition from Rohde & Schwarz is another strong validation of Bell’s strategic priority to deliver the best networks. Bell’s 5G+ network delivers the speed and performance Canadians expect, whether they’re streaming, gaming, working or staying connected on the go. Connection is everything, and we’re proud to see our continued investment recognized by another independent third party.”
– Blaik Kirby, Group President, Consumer and Small Business, Bell
“Based on our 2026 testing of national wireless networks in Canada, Bell delivered the top 5G/5G+ data performance, meaning subscribers can experience faster speeds and more reliable connections, especially in busy urban areas. At Rohde & Schwarz, independent network benchmarking is core to our mission. By providing operators with objective, real-world performance data, we help drive continuous improvement across the industry, ultimately benefiting every subscriber.”
– Axel Hansmann, CEO Rohde & Schwarz SwissQual AG
To learn more about 5G and 5G+ wireless, please visit Bell.ca/network.
About Bell
Bell is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.
1 Based on total revenue and total combined customer connections.
Media inquiries:
Patricia Garcia
media@bell.ca
Investor inquiries:
Krishna Somers
krishna.somers@bell.ca
SOURCE Bell Canada (MTL)
Technology
Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy
Published
37 minutes agoon
July 20, 2026By
Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care’s FDA 510(k)-cleared software platform for kidney replacement therapy in the United StatesAggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability
BAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ — Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, the Company’s FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise is designed to provide retrospective, program-level insight into kidney replacement therapy (KRT) delivered in acute and hospital critical care settings.
Kidney replacement therapy in the Intensive Care Unit (ICU) generates large volumes of clinical and operational data, yet trends related to therapy delivery, workflow interruptions, and alarm frequency can be difficult to assess without standardized metrics and aggregated views. TherapyWise consolidates existing data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods.
“Digital solutions play an increasingly important role in how critical care teams understand and manage complex therapies,” said Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care. “TherapyWise reflects our continued focus on innovation in critical care by applying data analytics. This helps hospital and clinical leaders gain visibility into how kidney replacement therapy is delivered across their organizations, supporting informed discussions around workflow, consistency, and quality improvement.”
TherapyWise works by securely transmitting data from the NxStage System One with NxView to a cloud‑based platform, where information is aggregated and displayed across predefined performance indicators. These include program‑level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended to support retrospective review and program oversight and is not designed for real‑time, patient‑specific clinical decision‑making, which remains the responsibility of attending clinicians.
TherapyWise is part of Fresenius Medical Care’s NxView 4.0 software platform and broader critical care portfolio, which combines digital infrastructure, clinical expertise, and secure data management to support hospital teams responsible for kidney replacement therapy programs.
To learn more about TherapyWise, please visit https://freseniusmedicalcare.com/en-us/products/critical-care/therapywise/.
About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-therapy-302829320.html
SOURCE Fresenius Medical Care Holdings, Inc.
Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network
Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network
Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoOstium pauses trading as security firms report multimillion-dollar oracle exploit
-
Coin Market5 days agoRevolut receives in-principle approval from UAE authorities for crypto services
-
Technology5 days agoGPU.ai Named Official Title Sponsor of AGI Summit SF 2026
-
Near Videos5 days agoThe best AI agents need your most sensitive data
-
Coin Market5 days agoAave launches V4 on Avalanche, laying groundwork for tokenized credit markets
-
Coin Market5 days agoCrypto firms face AML risks during post-MiCA migration, says AMLA chair
-
Technology5 days agoSandler Partners and Liminal Announce Strategic Partnership to Bring Secure Generative AI Solutions to Enterprise Customers Nationwide
-
Technology5 days agoNEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
